Human Genome Epidemiology Literature Finder
Records 1 - 11 (of 11 Records) |
Query Trace: Leukemia and BTK[original query] |
---|
Transcription factor PU.1 is involved in the progression of glioma. Oncology letters 2018 2 15 (3): 3753-3759. Xu Yuanzhi, Gu Song, Bi Yunke, Qi Xiangqian, Yan Yujin, Lou Meiqi |
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood 2019 6 134 (7): 641-644. Quinquenel Anne, Fornecker Luc-Matthieu, Letestu Rémi, Ysebaert Loïc, Fleury Carole, Lazarian Grégory, Dilhuydy Marie-Sarah, Nollet Delphine, Guieze Romain, Feugier Pierre, Roos-Weil Damien, Willems Lise, Michallet Anne-Sophie, Delmer Alain, Hormigos Katia, Levy Vincent, Cymbalista Florence, Baran-Marszak Fanny, |
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K? inhibitor therapy. Blood 2020 12 137 (20): 2817-2826. Mato Anthony R, Ghosh Nilanjan, Schuster Stephen J, Lamanna Nicole, Pagel John M, Flinn Ian W, Barrientos Jacqueline C, Rai Kanti R, Reeves James A, Cheson Bruce D, Barr Paul M, Kambhampati Suman, Lansigan Frederick, Pu Jeffrey J, Skarbnik Alan P, Roeker Lindsey, Fonseca Gustavo A, Sitlinger Andrea, Hamadeh Issam S, Dorsey Colleen, LaRatta Nicole, Weissbrot Hanna, Luning Prak Eline T, Tsao Patricia, Paskalis Dana, Sportelli Peter, Miskin Hari P, Weiss Michael S, Svoboda Jakub, Brander Danielle |
Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib. European journal of haematology 2020 Nov . Machnicki Marcin M, Górniak Patryk, P?pek Monika, Szymczyk Agnieszka, Iskierka-Ja?d?ewska El?bieta, Steckiewicz Pawe?, Bluszcz Aleksandra, Rydzanicz Ma?gorzata, Hus Marek, P?oski Rafa?, Makuch-?asica Hanna, Nowak Gra?yna, Juszczy?ski Przemys?aw, Jamroziak Krzysztof, Stok?osa Tomasz, Pu?a Barto |
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 10 39 (6): 576-585. Ahn Inhye E, Tian Xin, Ipe David, Cheng Mei, Albitar Maher, Tsao L Claire, Zhang Lei, Ma Wanlong, Herman Sarah E M, Gaglione Erika M, Soto Susan, Dean James P, Wiestner Adri |
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. Blood 2021 3 138 (1): 44-56. Murali Ishwarya, Kasar Siddha, Naeem Aishath, Tyekucheva Svitlana, Khalsa Jasneet K, Thrash Emily M, Itchaki Gilad, Livitz Dimitri, Leshchiner Ignaty, Dong Shuai, Fernandes Stacey M, Getz Gad, Johnson Amy, Brown Jennifer |
Genetic Predictors of Ibrutinib-Related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 9 . Issam S Hamadeh, Jai N Patel, Ryan Jacobs, Hang Zeng, Jiaxian He, Bei Hu, Tamara Kay Moyo, Amy Soni, Steven Park, Ed Copelan, Belinda Avalos, Alicia Hamilton, Nury Steuerwald, Nilanjan Gho |
B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 6 . Jennifer A Woyach, Paolo Ghia, John C Byrd, Inhye E Ahn, Carol Moreno, Susan M O'Brien, Daniel Jones, Leo W K Cheung, Elizabeth Chong, Kevin Kwei, James P Dean, Danelle F James, Adrian Wiestn |
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 5 OF1-OF10. Anfal Alsadhan, Jonathan Chen, Erika M Gaglione, Chingiz Underbayev, Pamela L Tuma, Xin Tian, Lita A Freeman, Sivasubramanian Baskar, Pia Nierman, Susan Soto, Andy Itsara, Inhye E Ahn, Clare Sun, Elena Bibikova, Tanja Nicole Hartmann, Maissa Mhibik, Adrian Wiestn |
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 11 OF1-OF8. Nitin Jain, Lisa J Croner, John N Allan, Tanya Siddiqi, Alessandra Tedeschi, Xavier C Badoux, Karl Eckert, Leo W K Cheung, Anwesha Mukherjee, James P Dean, Edith Szafer-Glusman, John F Seymo |
BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib. Blood advances 2023 1 . Bonfiglio Silvia, Sutton Lesley-Ann, Ljungström Viktor, Capasso Antonella, Pandzic Tatjana, Weström Simone, Foroughi-Asl Hassan, Skaftason Aron, Gellerbring Anna, Lyander Anna, Gandini Francesca, Gaidano Gianluca, Trentin Livio, Bonello Lisa, Reda Gianluigi, Bödör Csaba, Stavroyianni Niki, Tam Constantine S, Marasca Roberto, Forconi Francesco, Panayiotidis Panayiotis, Ringshausen Ingo, Jaksic Ozren, Frustaci Anna Maria, Iyengar Sunil, Coscia Marta, Mulligan Stephen P, Ysebaert Loïc, Strugov Vladimir, Pavlovsky Carolina, Walewska Renata, Österborg Anders, Cortese Diego, Ranghetti Pamela, Baliakas Panagiotis, Stamatopoulos Kostas, Scarfò Lydia, Rosenquist Richard, Ghia Pao |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: